Genuron's mission is to build computational models that decode the process of biological resilience at the cell and organ level so that therapies and longevity interventions - both standardized and personalized - can be generated from those models
Harnessing Big Data And Human Ingenuity For Future Scientific Breakthroughs
Rapid advancements in artificial intelligence and machine learning will transform our understanding of basic biological processes like ageing and disease. Genuron is producing powerful artificial intelligence models of life’s building blocks and their interactions within cells to produce machine learning platforms for designing therapies, reprogramming interventions, and unlocking protein targets, to transform how we treat disease and intervene in ageing
The Road Map towards Digital Biology Super Agents
Genuron R&D Strategy
Combine the rapid advances in generative artificial intelligence and machine learning with transformative advances in the understanding of human disease and in the science of therapeutic discovery to make previously unimagined advances in human health
Target Validation
Focus on targets that have been validated by deep machine learning that address causal disease or degeneration in human biology
Modality Neutral
Discover, validate, and bring to market medicines, therapies and interventions that are transformative to humans regardless of modality
Generative Lab Assays
Create innovative lab assays that harness generative AI to develop clinical biomarkers for personalized medicine
Platform Pathways
Shorten time to market and lock in IP by establishing AI-driven medicine platforms especially in the area of gene therapies
Project Pipeline
We are involved in several groundbreaking initiatives that investigate diverse therapeutic approaches aimed at combating cancer and other serious illnesses. Our research is designed to harness cutting-edge technology and scientific advancements to create novel treatment options
The services, products and technologies described on this website will be offered on a when-and-if-available basis and is subject to regulatory approvals in all territories. The statements on this website are not intended to be - and should not be interpreted as - a commitment, promise, or legal obligation, and the development, release, and timing of any services, products and technologies described is subject to change, and it remains at the sole discretion of GENURON to deliver or delay the delivery of any of the products, services, or technologies set forth herein. GENURON is a start-up company and statements in this website are forward-looking statements that are subject to considerable risk and uncertainty. Important factors that could cause actual results, products, services or technologies to differ materially include: failure to produce drugs or therapies as expected by our scientists; regulatory rejection of our products or technologies; consumer rejection of our products and technologies; design or manufacturing defects; changes in industry standards; unexpected loss of performance of our products or technologies when used by third parties; and reputational risks. These forward-looking statements are not guarantees of future performance and, except as required by law, GENURON disclaims any obligation to update these forward-looking statements to reflect future events or circumstances.